CPRC
NVO

Consolidated Portfolio Review Corp’s Novo Nordisk NVO Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14,473
Closed -$1.86M – 306
2024
Q1 		$1.86M Hold
14,473
– – 0.49% 60
2023
Q4 		$1.5M Buy
+14,473
New +$1.43M 0.34% 77

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Consolidated Portfolio Review Corp's NVO Position: Q2 2024 in Review

Consolidated Portfolio Review Corp sold out of Novo Nordisk (NVO) in Q2 2024, closing a stake of 14,473 shares — an estimated $1.86M sold.

Consolidated Portfolio Review Corp first reported a position in NVO in Q4 2023 and held it in 2 quarters. The position peaked at $1.86M in Q1 2024. 1,860 funds tracked by Wall St. Rank hold NVO as of Q2 2024.

  • Consolidated Portfolio Review Corp reported no remaining Novo Nordisk position as of Q2 2024 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 14,473 Novo Nordisk shares in Q2 2024, an estimated $1.86M.
  • Consolidated Portfolio Review Corp first reported a position in Novo Nordisk in Q4 2023 and held it in 2 quarters.
  • Consolidated Portfolio Review Corp's Novo Nordisk position peaked at $1.86M in Q1 2024.
  • 1,860 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2024.

Based on Consolidated Portfolio Review Corp's 13F filing for Q2 2024, filed 1 Aug 2024.